Pathogenesis of pre-neoplastic lesions of the stomach: Targets for prevention

Digestive Diseases

Volumn 22, Issue 4, 2004, Pages 306-312

  Leung, Wai K ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Atrophy; Gastric cancer; Helicobacter pylori; Intestinal metaplasia

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; ASCORBIC ACID; BETA CAROTENE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; PROSTAGLANDIN SYNTHASE INHIBITOR;

ATROPHY; BACTERIAL GENETICS; BACTERIAL VIRULENCE; CANCER PREVENTION; CELL KINETICS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIET; DISEASE COURSE; DRUG TARGETING; EPIGENETICS; GASTROINTESTINAL TOXICITY; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMEOBOX; HOST; HUMAN; INFLAMMATION; INTESTINE METAPLASIA; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH LESION; STOMACH TUMOR; TRANSCRIPTION INITIATION; VITAMIN SUPPLEMENTATION; ANIMAL; RISK FACTOR;

ANIMALS; CYCLOOXYGENASE INHIBITORS; HUMANS; PRECANCEROUS CONDITIONS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 21844439018     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083591     Document Type: Review

References (60)

1. Ferlay J, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5, vers 2.0. Lyon, IARC Press, 2004.
2. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process. First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-6740.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, liver flukes and Helicobacter pylori, Lyon, June 7-14, 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
4. Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179.
5. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
6. Dixon MF: Prospects for intervention in gastric carcinogenesis: Reversibility of gastric atrophy and intestinal metaplasia. Gut 2001;49:2-4.
7. Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, Fraumeni JF Jr, Adami HO: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-249.
8. Tsukui T, Kashiwagi R, Sakane M, Tabata F, Akamatsu T, Wada K, Futagami S, Miyake K, Sueoka N, Hirakawa T, Kobayashi M, Fujimori T, Sakamoto C: Aging increase, and duodenal ulcer reduces the risk of intestinal metaplasia of the gastric corpus in Japanese patients with dyspepsia. J Gastroenterol Hepatol 2001;16:15-21.
9. Chan FKL, Leung WK: Peptic-ulcer disease. Lancet 2002;360:933-941.
10. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF Jr, Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
11. Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S, Castro Alves C, Campos ML, Van Doorn LJ, Caldas C, Seruca R, Carneiro F, Sobrinho-Simoes M: A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003;125:364-371.
12. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doorn LJ, Carneiro F, Sobrinho-Simoes M: Helicobacter pylori and interleukin-1 genotyping: An opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002;94:1680-1687.
13. Zeng ZR, Hu PJ, Hu S, Pang RP, Chen MH, Ng M, Sung JJ: Association of interleukin-1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 2003;52:1684-1689.
14. Rad R, Prinz C, Neu B, Neuhofer M, Zeitner M, Voland P, Becker I, Schepp W, Gerhard M: Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. J Infect Dis 2003;188:272-281.
15. Nogueira C, Figueiredo C, Carneiro F, Gomes AT, Barreira R, Figueira P, Salgado C, Belo L, Peixoto A, Bravo JC, Bravo LE, Realpe JL, Plaisier AP, Quint WG, Ruiz B, Correa P, van Doorn LJ: Helicobacter pylori genotypes may determine gastric histopathology. Am J Pathol 2001;158:647-654.
16. Yu J, Leung WK, Go MY, Chan MC, To KF, Ng EK, Chan FK, Ling TK, Chung SC, Sung JJ: Relationship between Helicobacter pylori babA2 status with gastric epithelial cell turnover and pre-malignant gastric lesions. Gut 2002;51:480-484.
17. Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC: High-salt diet induces gastric epithelial hyperplasia and parietal cell loss and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999;59:4823-4828.
18. Rood JC, Ruiz B, Fontham ET, Malcom GT, Hunter FM, Sobhan M, Johnson WD, Correa P: Helicobacter pylori-associated gastritis and the ascorbic acid concentration in gastric juice. Nutr Cancer 1994;22:65-72.
19. Zhang ZW, Patchett SE, Perrett D, Katelaris PH, Domizio P, Farthing MJ: The relation between gastric vitamin C concentrations, mucosal histology, and cagA seropositivity in the human stomach. Gut 1998;43:322-326.
20. Su L, Fontham E, Ruiz B, Schmidt S, Correa P, Bravo L: Association of dietary antioxidants on the severity of gastritis in a high risk population. Ann Epidemiol 2000;10:468.
21. Moss SF, Calam J, Agarwal B, Wang S, Holt PR: Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut 1996;38:498-501.
22. Peek RM Jr, Moss SF, Tham KT, Perez-Perez GI, Wang S, Miller GG, Atherton JC, Holt PR, Blaser MJ: Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis. J Natl Cancer Inst 1997;89:863-868.
23. Leung WK, To KF, Chan FKL, Lee TL, Chung SCS, Sung JJY: Interaction of H. pylori and NSAID on gastric epithelial cell apoptosis and proliferation: Implications on ulcerogenesis. Aliment Pharmacol Ther 2000;14:879-885.
24. Leung WK, Yu J, To KF, Go MY, Ma PK, Chan FK, Sung JJ: Apoptosis and proliferation in Helicobacter pylori-associated gastric intestinal metaplasia. Aliment Pharmacol Ther 2001;15:1467-1472.
25. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol 1994;144:511-517.
26. Wu MS, Shun CT, Lee WC, Chen CJ, Wang HP, Lee WJ, Sheu JC, Lin JT: Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer 1998;78:971-973.
27. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Kato Y, Yanagisawa A, Nakamura Y: The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992;52:3231-3233.
28. Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
29. Wang D, Dubois RN: Cyclooxygenase-2: A potential target in breast cancer. Semin Oncol 2004;31(suppl 3):64-73.
30. Sung JJY, Leung WK, Go MYY, To KF, Cheng AS, Ng EK, Chan FK: Cyclooxygenase-2 expression in Helicobacter pylori-associated pre-malignant and malignant gastric lesions. Am J Pathol 2000;157:729-735.
31. Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, Ng EK, Chung SC, Sung JJ: Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer 2001;84:335-339.
32. Chan FK, To KF, Ng YP, Lee TL, Cheng AS, Leung WK, Sung JJ: Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis. Aliment Pharmacol Ther 2001;15:187-193.
33. Tsujii M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995;83:493-501.
34. Filipe MI, Osborn M, Linehan J, Sanidas E, Brito MJ, Jankowski J: Expression of transforming growth factor-α, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. Br J Cancer 1995;71:30-36.
35. Yu J, Leung WK, Ng EK, To KF, Ebert MP, Go MY, Chan WY, Chan FK, Chung SC, Malfertheiner P, Sung JJ: Effect of H. pylori eradication on expression of cyclin D2 and p27 in gastric intestinal metaplasia. Aliment Pharmacol Ther 2001;15:1505-1512.
36. Yamamoto H, Bai YQ, Yuasa Y: Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 2003;300:813-818.
37. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, Kenji Yagi O, Saitoh K, Takeshita K, Iwai T, Yuasa Y: Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett 2002;176:47-55.
38. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH: CDX2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002;122:689-696.
39. Hinoi T, Lucas PC, Kuick R, Hanash S, Cho KR, Fearon ER: CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology 2002;123:1565-1577.
40. Mutoh H, Sakurai S, Satoh K, Osawa H, Hakamata Y, Takeuchi T, Sugano K: CDX1 induced intestinal metaplasia in the transgenic mouse stomach: Comparative study with CDX2 transgenic mice. Gut 2004;53:1416-1423.
41. Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M: Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999;116:1348-1357.
42. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR: Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol 2000;156:537-543.
43. Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC: hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 1999;59:159-164.
44. Leung WK, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC, Sung JJ: Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. Cancer 2001;91:2294-2301.
45. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, Ng EK, Chung SC, Sung JJ: Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002;102:623-628.
46. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH, Hui WM, Rashid A, Kwong YL: Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003;52:502-506.
47. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumii K, Kajiyama G: Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997;6:639-642.
48. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, Yokoyama T, Watanabe M: Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-386.
49. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter therapy. J Natl Cancer Inst 2000;92:1881-1888.
50. Sung JJY, Lin SR, Ching JYL, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, Yeung CK, Chao W, Chung SC: Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14.
51. Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, Xia Z, Guo H, Liu J, Chao W: A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J 2003;116:11-14.
52. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ: Factors predicting progression of gastric intestinal metaplasia: Results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249.
53. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N: Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16:1923-1932.
54. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS: China Gastric Cancer Study Group: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China. A randomized controlled trial. JAMA 2004;291:187-194.
55. Zullo A, Rinaldi V, Hassan C, Diana F, Winn S, Castagna G, Attili AF: Ascorbic acid and intestinal metaplasia in the stomach: A prospective randomized study. Aliment Pharmacol Ther 2000;14:1303-1309.
56. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000;320:1642-1646.
57. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC: Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: A systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784-1791.
58. Dannenberg AJ, Subbaramaiah K: Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003;4:431-436.
59. Hu PJ, Yu J, Zeng ZR, Leung WK, Lin HL, Tang BD, Bai AH, Sung JJ: Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200.
60. Yu J, Tang BD, Leung WK, Zeng ZR, Yo KF, Bai AHC, Ma PK, Go MYY, Hu PJ, Sung JJY: Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention. World J Gastroenterol 2005;11:41-45.